

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10726198
Filing Date		2002-06-10
First Named Inventor	JOHN, Constance M.	
Art Unit	1643	
Examiner Name	REDDIG, Peter J.	
Attorney Docket Number	81217-358194	

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10726198
Filing Date		2002-06-10
First Named Inventor	JOHN, Constance M.	
Art Unit	1643	
Examiner Name	REDDIG, Peter J.	
Attorney Docket Number	81217-358194	

1	BRESALIER, R.S. et al., "Metastasis of Human Colon Cancer is Altered by Modifying Expression of the β -Galactoside-Binding Protein Galectin 3" Gastroenterology (1998) 115:287-296	<input type="checkbox"/>
2	CASTRONOVO, V. et al., "Decreased Expression of Galectin-3 Is Associated With Progression of Human Breast Cancer," J. Pathology (1996) 179:43-48	<input type="checkbox"/>
3	CHOI, J-H. et al., "Inhibition of N-(4-hydroxyphenyl)retinamide-Induced Apoptosis in Breast Cancer Cells by Galectin-3," Cancer Biology & Therapy (May 2004) 3:5, pp. 447-452	<input type="checkbox"/>
4	COULDREY, C. and GREEN, J.E., "Metastases: the glycan connection," Breast Cancer Res. (2000) 2:321-323	<input type="checkbox"/>
5	GAUDIN, J-C et al., "Nuclear localization of wild type and mutant galectin-3 in transfected cells," Biology of the Cell (2000) 92:49-58	<input type="checkbox"/>
6	GONG, H.C. et al., "The NH2 Terminus of Galectin-3 Governs Cellular Compartmentalization and Functions in Cancer Cells," Cancer Res. (Dec 1999) 59:6239-6245	<input type="checkbox"/>
7	GRANOVSKY, M. et al., "Suppression of tumor growth and metastasis in Mgat5-deficient mice," Nature Medicine (Mar 2000) 6(3):306-312	<input type="checkbox"/>
8	HONJO, Y. et al., "Down-Regulation of Galectin-3 Suppresses Tumorigenicity of Human Breast Carcinoma Cells," Clin. Cancer Res. (Mar 2001) 7:661-668	<input type="checkbox"/>
9	HSU, D. et al., "Biochemical and Biophysical Characterization of Human Recombinant IgE-binding Protein, an S-type Animal Lectin," J. Biol. Chem. (Jul 1992) 267(20):14167-14174	<input type="checkbox"/>
10	INOHARA, H. and RAZ, A., "Functional Evidence that Cell Surface Galectin-3 Mediates Homotypic Cell Adhesion," Cancer Res. (Aug 1995) 55:3267-3271	<input type="checkbox"/>
11	IURISCI, I. et al., "Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients," Clin. Cancer Res. (April 2000) 6:1389-1393	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10726198
Filing Date	2002-06-10
First Named Inventor	JOHN, Constance M.
Art Unit	1643
Examiner Name	REDDIG, Peter J.
Attorney Docket Number	81217-358194

12	KIM, H-R. C. et al, "Cell Cycle Arrest and Inhibition of Anoikis by Galectin-3 in Human Breast Epithelial Cells," Cancer Res. (Aug 1999) 59:4148-4154	<input type="checkbox"/>
13	KUWABARA, I, and LIU, F-T., "Galectin-3 Promotes Adhesion of Human Neutrophils to Laminin," J. Immunol., (May 1996) 156:3939-3944	<input type="checkbox"/>
14	LIN, H-M. et al., "Galectin-3 mediates genistein-induced G2/M arrest and inhibits apoptosis," Carcinogenesis (2000) 21 (11):1941-1945	<input type="checkbox"/>
15	LIU, F-T. et al., "Modulation of Functional Properties of Galectin-3 by Monoclonal Antibodies Binding to the Non-Lectin Domains," Biochemistry (1996) 35:6073-6079	<input type="checkbox"/>
16	LOTZ, M.M. et al., "Decreased expression of Mac-2 (carbohydrate binding protein 35) and loss of its nuclear localization are associated with the neoplastic progression of colon carcinoma," Proc. Natl. Acad. Sci. USA (Apr 1993) 90:3466-3470	<input type="checkbox"/>
17	NANGIA-MAKKER, P. et al., "Galectin-3 and L1 retrotransposons in human breast carcinomas," Breast Cancer Res. and Treatment (1998) 49:171-183	<input type="checkbox"/>
18	MASSA, S. M., "L-29, an Endogenous Lectin, Binds to Glycoconjugate Ligands with Positive Cooperativity," Biochemistry (1993) 32:260-267	<input type="checkbox"/>
19	MORIKI, T. et al., "Protein Domain Mapping by λ Phage Display: The Minimal Lactose-Binding Domain of Galectin-3," Biochem. Biophys. Res. Commun. (1999) 265:291-296	<input type="checkbox"/>
20	NANGIA-MAKKER, P. et al., "Galectin-3 Induces Endothelial Cell Morphogenesis and Angiogenesis," Am. J. Pathol. (March 2000) 156(3):899-909	<input type="checkbox"/>
21	OCHIENG, J. et al., "Structure-Function Relationship of a Recombinant Human Galactoside-Binding Protein," Biochemistry (1993) 32:4455-4460	<input type="checkbox"/>
22	OCHIENG, J. and WARFIELD, P., "Galectin-3 Binding Potentials of Mouse Tumor EHS and Human Placental Laminins," Biochem. Biophys. Res. Commun. (Dec 1995) 217(2):402-406	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10726198
Filing Date		2002-06-10
First Named Inventor	JOHN, Constance M.	
Art Unit	1643	
Examiner Name	REDDIG, Peter J.	
Attorney Docket Number	81217-358194	

23	OCHIENG, J. et al., "Galectin-3 Regulates the Adhesive Interaction Between Breast Carcinoma Cells and Elastin," J. Cell. Biochem. (1999) 75:505-514	<input type="checkbox"/>
24	ODA, Y. et al., "Human breast carcinoma cDNA encoding a galactoside-binding lectin homologous to mouse Mac-2 antigen," Gene (1991) 99:279-283	<input type="checkbox"/>
25	OKA, N. et al., "Galectin-3 Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells," Cancer Res. (Sep 2005) 65(17) 7546-7553	<input type="checkbox"/>
26	RAZ, A. et al., "Identification of the Metastasis-associated, Galactoside-binding Lectin as a Chimeric Gene Product with Homology to an IgE-binding Protein," Cancer Res. (July 1989) 49:3489-3493	<input type="checkbox"/>
27	SAUSSEZ, S. et al., "The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy," Oral Oncol. (2007) IN PRESS, 8 pp	<input type="checkbox"/>
28	SEETHARAMAN, J. et al., "X-ray Crystal Structure of the Human Galectin-3 Carbohydrate Recognition Domain at 2.1-Å Resolution," J. Biol. Chem. (May 1998) 273(21):130047-13052	<input type="checkbox"/>
29	TAKENAKA, Y. et al., "Malignant transformation of thyroid follicular cells by galectin-3," Cancer Lett (2003) 195:111-119	<input type="checkbox"/>
30	YAMAOKA, A. et al., "A Human Lectin, Galectin-3 (cbp/Mac-2), Stimulates Superoxide Production by Neutrophils," J. Immunol. (Apr 1995) 154: 3479-3487	<input type="checkbox"/>
31	OCHIENG, J. et al., "Modulation of the biological functions of galectin-3 by matrix metalloproteinases," Biochim. Biophys. Acta (1998) 1379:97-106	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10726198
Filing Date	2002-06-10
First Named Inventor	JOHN, Constance M.
Art Unit	1643
Examiner Name	REDDIG, Peter J.
Attorney Docket Number	81217-358194

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

- ☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).


OR

- ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature		Date (YYYY-MM-DD)	2007-08-27
Name/Print	Richard A. Nakashima	Registration Number	42,023

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.